RaQualia Pharma Inc. agreed to acquire FIMECS, Inc. from Nissay Capital No. 11 Investment Limited Partnership and Nissay Capital Co., Ltd. for ¥4.5 billion.

RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.